KUALA LUMPUR, Feb 17 -- Taconic Biosciences’ humanised immune system mice models are now being produced in Europe, helping to create effective new treatments against various cancer forms.
According to a statement, the production provides European drug discovery researchers with easier access to this critical oncology research tool.
Taconic’s humanised models are built upon the NOG Portfolio, a suite of immunodeficient mice that support engraftment and/or differentiation of various human immune cells.
Both the huNOG and huNOG-EXL models are now available for off-the-shelf sales from local European inventory.
“The human immune system is incredibly complex and immuno-oncology may be the starkest example of how animal models contribute to scientific breakthroughs by helping researchers understand, and even leverage that complexity,” said Taconic commercial models vice-president, Dr Michael Seiler.
“It is only when these great tools are combined with the right scientific expertise do we see success. Taconic leverages internal expertise plus external collaborations to provide insightful data on these critical models.”
According to the American Cancer Society, there will be 1.8 million new cancer diagnoses this year. Thus, the global bio-pharmaceutical industry continues its focus, specifically on cancer and immuno-oncology.
-- BERNAMA
No comments:
Post a Comment